Marea Therapeutics, a subsidiary of Lisata Therapeutics, will participate in key investor conferences in November, including the Guggenheim Healthcare Innovation Conference and Jefferies Global Healthcare Conference. The company is advancing its lead drug candidate MAR001 for severe hypertriglyceridemia and MAR002 for acromegaly, both in clinical development stages. These presentations aim to update investors on progress and future plans for these cardioendocrine disease treatments. Webcasts of the events will be available on Lisata's investor website for broader access.
Marea Therapeutics' upcoming investor conference participation is context for readers. For those tracking the Health sector, 87 of 150 US stocks rose and 56 fell on Pluang. Notable movers as of Nov 05, 2026 19:42 WIB include Edwards Lifesciences (EW) at USD 103.00, up 3.65%, Zoetis (ZTS) at USD 92.33, up 3.54%, and Takeda Pharmaceutical (TAK) at USD 21.80, up 3.51%.
On November 4, 2026, Shell plc repurchased a total of 1,876,276 shares across multiple trading venues including LSE, Chi-X, BATS, XAMS, CBOE, and TQEX. The shares were bought at prices ranging from £37.98 to £38.82 and €45.70 to €46.72, with an avera...
Dune has completed a SOC 2 Type II examination with no exceptions, providing institutional clients with verified assurance of its data security standards. This milestone comes as tokenized real-world assets doubled to $32.6 billion and stablecoin mar...
Northern Discovery Metals has finalized the acquisition of a 100% interest in the Cibola copper-gold project in British Columbia from Orogen Royalties. The project covers about 3,567 hectares near Houston, BC, in a region known for porphyry copper de...
Opus Genetics has finished dosing the higher-dose Cohort 2 in its Phase 1/2 trial of OPGx-BEST1, a gene therapy for BEST1-related inherited retinal diseases like Best vitelliform macular dystrophy and autosomal recessive bestrophinopathy. Cohort 2 en...
Perimeter Group Inc. announced a net income of $304.5 million for Q3 2026, reversing a prior year loss of $90.7 million, with net sales up 24% to $389.9 million. Growth was driven by a 14% increase in Fire Safety sales and an 84% surge in Specialty P...
